Walker Luke Nathaniel 4

What Happened Walker Luke Nathaniel, a director of Zentalis Pharmaceuticals (ZNTL), received a grant of 57,100 restricted stock units (RSUs) on June 16, 2026. The award was recorded at $0.00 per unit (total reported value $0) and represents a contingent right to one share of common stock per RSU that will convert to shares upon vesting.

Key Details

• Transaction type/date: Award/Grant (Code A) on 2026-06-16 at $0.00 per RSU.
• Amount: 57,100 RSUs granted. Reported total value: $0.
• Vesting: RSUs vest on the earlier of (a) June 16, 2027 or (b) the next annual meeting of stockholders, subject to the director’s continued board service (see footnote F1).
• Shares owned after transaction: Not specified in this filing.
• Timeliness: Form 4 filed 2026-06-18 for a 2026-06-16 transaction—within the typical 2-business-day reporting window.
• Exhibit/Remark: Exhibit 24 (Power of Attorney) included.

Context This is a routine non-cash director compensation grant (RSUs) under Zentalis’s Non-Employee Director Compensation Program. Such awards compensate board service and do not represent an immediate purchase or sale of shares; shares will only be issued if and when the RSUs vest. For retail investors, grants to directors are common and are generally informational rather than a direct market signal.